To determine if targeting ATGL would have an inhibitory effect on heterogenic colon cancer cell populations, we utilized two CCC lines, HCT116 and HT29, with different approaches of ATGL targeting: shRNA and atglistatin. Here, PNPLA2 is linked to colonic neoplasm.